Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBITDA Margin (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed EBITDA Margin for 6 consecutive years, with 12.91% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 2144.0% year-over-year to 12.91%, compared with a TTM value of 0.19% through Dec 2025, up 2719.0%, and an annual FY2025 reading of 0.19%, up 2719.0% over the prior year.
  • EBITDA Margin was 12.91% for Q4 2025 at Xeris Biopharma Holdings, up from 0.83% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 12.91% in Q4 2025 and bottomed at 309.06% in Q2 2021.
  • Average EBITDA Margin over 5 years is 82.5%, with a median of 42.85% recorded in 2022.
  • The sharpest move saw EBITDA Margin crashed -8900bps in 2021, then surged 20564bps in 2022.
  • Year by year, EBITDA Margin stood at 234.19% in 2021, then skyrocketed by 83bps to 38.97% in 2022, then grew by 23bps to 30.11% in 2023, then skyrocketed by 72bps to 8.52% in 2024, then surged by 252bps to 12.91% in 2025.
  • Business Quant data shows EBITDA Margin for XERS at 12.91% in Q4 2025, 0.83% in Q3 2025, and 2.69% in Q2 2025.